A review of remdesivir for COVID-19 in pregnancy and lactation
Mounting evidence suggests that pregnant people have an elevated risk of severe COVID-19-related complications compared with their non-pregnant counterparts, underscoring the need for effective prevention and treatment strategies. However, despite progress in innovative and flexible trial designs du...
Gespeichert in:
| Veröffentlicht in: | Journal of antimicrobial chemotherapy 2021-12, Vol.77 (1), p.24-30 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 30 |
|---|---|
| container_issue | 1 |
| container_start_page | 24 |
| container_title | Journal of antimicrobial chemotherapy |
| container_volume | 77 |
| creator | Jorgensen, Sarah C J Davis, Matthew R Lapinsky, Stephen E |
| description | Mounting evidence suggests that pregnant people have an elevated risk of severe COVID-19-related complications compared with their non-pregnant counterparts, underscoring the need for effective prevention and treatment strategies. However, despite progress in innovative and flexible trial designs during the COVID-19 pandemic, regressive policies excluding pregnant and breastfeeding people from biomedical research persist. Remdesivir, a broad-spectrum antiviral, was the first drug licensed for the treatment of COVID-19, based on data showing it reduced the time to recovery in hospitalized patients. Pregnant and breastfeeding people were specifically excluded from all clinical trials of remdesivir in COVID-19, but data are accumulating from post-marketing registries, compassionate use programmes and case series/reports. In this review we synthesize these data and highlight key knowledge gaps to help inform clinical decision-making about its use in pregnancy and lactation. |
| doi_str_mv | 10.1093/jac/dkab311 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8499800</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>34427297</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-523e1570253555c9268df485e4e6fb9d3fffd9824dd396b4a0122f046242f6923</originalsourceid><addsrcrecordid>eNpVkE1LAzEQhoMotlZP3iV3WTv53M2lUOpXodCLeg3ZTVJT22zJrpX-e1dai55mYN73GXgQuiZwR0Cx4dJUQ_thSkbICeoTLiGjoMgp6gMDkeVcsB66aJolAEghi3PUY5zTnKq8j0ZjnNw2uC9c-25bW9eEbUjY1wlP5m_T-4woHCLeJLeIJlY7bKLFK1O1pg11vERn3qwad3WYA_T6-PAyec5m86fpZDzLKg6qzQRljogcqGBCiEpRWVjPC-G4k75UlnnvrSoot5YpWXIDhFIPXFJOvVSUDdBoz918lmtnKxfbZFZ6k8LapJ2uTdD_LzG860W91QVXqgDoALd7QJXqpknOH7sE9I9G3WnUB41d-ubvu2P21xv7BvH1bkE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A review of remdesivir for COVID-19 in pregnancy and lactation</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Jorgensen, Sarah C J ; Davis, Matthew R ; Lapinsky, Stephen E</creator><creatorcontrib>Jorgensen, Sarah C J ; Davis, Matthew R ; Lapinsky, Stephen E</creatorcontrib><description>Mounting evidence suggests that pregnant people have an elevated risk of severe COVID-19-related complications compared with their non-pregnant counterparts, underscoring the need for effective prevention and treatment strategies. However, despite progress in innovative and flexible trial designs during the COVID-19 pandemic, regressive policies excluding pregnant and breastfeeding people from biomedical research persist. Remdesivir, a broad-spectrum antiviral, was the first drug licensed for the treatment of COVID-19, based on data showing it reduced the time to recovery in hospitalized patients. Pregnant and breastfeeding people were specifically excluded from all clinical trials of remdesivir in COVID-19, but data are accumulating from post-marketing registries, compassionate use programmes and case series/reports. In this review we synthesize these data and highlight key knowledge gaps to help inform clinical decision-making about its use in pregnancy and lactation.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/dkab311</identifier><identifier>PMID: 34427297</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Adenosine Monophosphate - analogs & derivatives ; Alanine - analogs & derivatives ; Alanine - therapeutic use ; Antiviral Agents - therapeutic use ; Breast Feeding ; COVID-19 - drug therapy ; Female ; Humans ; Lactation ; Pandemics ; Pregnancy ; Pregnancy Complications, Infectious - drug therapy ; Review ; SARS-CoV-2</subject><ispartof>Journal of antimicrobial chemotherapy, 2021-12, Vol.77 (1), p.24-30</ispartof><rights>The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.</rights><rights>The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-523e1570253555c9268df485e4e6fb9d3fffd9824dd396b4a0122f046242f6923</citedby><cites>FETCH-LOGICAL-c409t-523e1570253555c9268df485e4e6fb9d3fffd9824dd396b4a0122f046242f6923</cites><orcidid>0000-0002-7998-2312</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,778,782,883,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34427297$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jorgensen, Sarah C J</creatorcontrib><creatorcontrib>Davis, Matthew R</creatorcontrib><creatorcontrib>Lapinsky, Stephen E</creatorcontrib><title>A review of remdesivir for COVID-19 in pregnancy and lactation</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>Mounting evidence suggests that pregnant people have an elevated risk of severe COVID-19-related complications compared with their non-pregnant counterparts, underscoring the need for effective prevention and treatment strategies. However, despite progress in innovative and flexible trial designs during the COVID-19 pandemic, regressive policies excluding pregnant and breastfeeding people from biomedical research persist. Remdesivir, a broad-spectrum antiviral, was the first drug licensed for the treatment of COVID-19, based on data showing it reduced the time to recovery in hospitalized patients. Pregnant and breastfeeding people were specifically excluded from all clinical trials of remdesivir in COVID-19, but data are accumulating from post-marketing registries, compassionate use programmes and case series/reports. In this review we synthesize these data and highlight key knowledge gaps to help inform clinical decision-making about its use in pregnancy and lactation.</description><subject>Adenosine Monophosphate - analogs & derivatives</subject><subject>Alanine - analogs & derivatives</subject><subject>Alanine - therapeutic use</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Breast Feeding</subject><subject>COVID-19 - drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Lactation</subject><subject>Pandemics</subject><subject>Pregnancy</subject><subject>Pregnancy Complications, Infectious - drug therapy</subject><subject>Review</subject><subject>SARS-CoV-2</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkE1LAzEQhoMotlZP3iV3WTv53M2lUOpXodCLeg3ZTVJT22zJrpX-e1dai55mYN73GXgQuiZwR0Cx4dJUQ_thSkbICeoTLiGjoMgp6gMDkeVcsB66aJolAEghi3PUY5zTnKq8j0ZjnNw2uC9c-25bW9eEbUjY1wlP5m_T-4woHCLeJLeIJlY7bKLFK1O1pg11vERn3qwad3WYA_T6-PAyec5m86fpZDzLKg6qzQRljogcqGBCiEpRWVjPC-G4k75UlnnvrSoot5YpWXIDhFIPXFJOvVSUDdBoz918lmtnKxfbZFZ6k8LapJ2uTdD_LzG860W91QVXqgDoALd7QJXqpknOH7sE9I9G3WnUB41d-ubvu2P21xv7BvH1bkE</recordid><startdate>20211224</startdate><enddate>20211224</enddate><creator>Jorgensen, Sarah C J</creator><creator>Davis, Matthew R</creator><creator>Lapinsky, Stephen E</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7998-2312</orcidid></search><sort><creationdate>20211224</creationdate><title>A review of remdesivir for COVID-19 in pregnancy and lactation</title><author>Jorgensen, Sarah C J ; Davis, Matthew R ; Lapinsky, Stephen E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-523e1570253555c9268df485e4e6fb9d3fffd9824dd396b4a0122f046242f6923</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adenosine Monophosphate - analogs & derivatives</topic><topic>Alanine - analogs & derivatives</topic><topic>Alanine - therapeutic use</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Breast Feeding</topic><topic>COVID-19 - drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Lactation</topic><topic>Pandemics</topic><topic>Pregnancy</topic><topic>Pregnancy Complications, Infectious - drug therapy</topic><topic>Review</topic><topic>SARS-CoV-2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jorgensen, Sarah C J</creatorcontrib><creatorcontrib>Davis, Matthew R</creatorcontrib><creatorcontrib>Lapinsky, Stephen E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jorgensen, Sarah C J</au><au>Davis, Matthew R</au><au>Lapinsky, Stephen E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A review of remdesivir for COVID-19 in pregnancy and lactation</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>2021-12-24</date><risdate>2021</risdate><volume>77</volume><issue>1</issue><spage>24</spage><epage>30</epage><pages>24-30</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><abstract>Mounting evidence suggests that pregnant people have an elevated risk of severe COVID-19-related complications compared with their non-pregnant counterparts, underscoring the need for effective prevention and treatment strategies. However, despite progress in innovative and flexible trial designs during the COVID-19 pandemic, regressive policies excluding pregnant and breastfeeding people from biomedical research persist. Remdesivir, a broad-spectrum antiviral, was the first drug licensed for the treatment of COVID-19, based on data showing it reduced the time to recovery in hospitalized patients. Pregnant and breastfeeding people were specifically excluded from all clinical trials of remdesivir in COVID-19, but data are accumulating from post-marketing registries, compassionate use programmes and case series/reports. In this review we synthesize these data and highlight key knowledge gaps to help inform clinical decision-making about its use in pregnancy and lactation.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>34427297</pmid><doi>10.1093/jac/dkab311</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-7998-2312</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0305-7453 |
| ispartof | Journal of antimicrobial chemotherapy, 2021-12, Vol.77 (1), p.24-30 |
| issn | 0305-7453 1460-2091 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8499800 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry |
| subjects | Adenosine Monophosphate - analogs & derivatives Alanine - analogs & derivatives Alanine - therapeutic use Antiviral Agents - therapeutic use Breast Feeding COVID-19 - drug therapy Female Humans Lactation Pandemics Pregnancy Pregnancy Complications, Infectious - drug therapy Review SARS-CoV-2 |
| title | A review of remdesivir for COVID-19 in pregnancy and lactation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T09%3A00%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20review%20of%20remdesivir%20for%20COVID-19%20in%20pregnancy%20and%20lactation&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Jorgensen,%20Sarah%20C%20J&rft.date=2021-12-24&rft.volume=77&rft.issue=1&rft.spage=24&rft.epage=30&rft.pages=24-30&rft.issn=0305-7453&rft.eissn=1460-2091&rft_id=info:doi/10.1093/jac/dkab311&rft_dat=%3Cpubmed_cross%3E34427297%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/34427297&rfr_iscdi=true |